Home Stock

Stock Research: Aspen Pharmacare

Independent, rules-based stock research to judge this stock's true performance: Cut through market noise and find high-growth or high-value gems from 8,000+ stocks worldwide.

Aspen Pharmacare

JNB:APN ZAE000066692
45
  • Value
    84
  • Growth
    8
  • Safety
    Safety
    53
  • Combined
    29
  • Sentiment
    88
  • 360° View
    360° View
    45
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Aspen Pharmacare Holdings Limited is a global pharmaceutical company. It focuses on marketing and manufacturing a range of post-patent, branded medicines and domestic brands covering both hospital and consumer markets, including the key brands Arixtra, Diprivan, Fraxiparine, Marcaine, Sustanon, and Xylocaine. Aspen Pharmacare Holdings Limited operates in South Africa and other global markets. In the last fiscal year, the company had a market cap of $2,813 million, profits of $1,070 million, revenue of $2,458 million, and 8,867 employees.

more

ANALYSIS: With an Obermatt 360° View of 45 (better than 45% compared with alternatives), overall professional sentiment and financial characteristics for the stock Aspen Pharmacare are below the industry average. The 360° View is based on consolidating four consolidated indicators, with half of the indicators below and half above average for Aspen Pharmacare. The consolidated Value Rank has an attractive rank of 84, which means that the share price of Aspen Pharmacare is on the lower side compared with typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 84% of alternative stocks in the same industry. The company is also safely financed with a Safety rank of 53. In addition, professional market sentiment is above average compared with other stock investment alternatives with a Sentiment Rank of 88. But the consolidated Growth Rank has a low rank of 8, which means that the company is below average in terms of growth and momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. 92 of its competitors have better growth. ...read more

more
Strongest Rank Capital Growth
Weakest Rank Pro Holdings
Country South Africa
Industry Pharmaceuticals
Size Large
Website aspenpharma.com
Index
JSE All Shares
Aspen Pharmacare stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 13-Mar-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
84 91 99 89
Growth
8 27 45 77
Safety
Safety
53 39 41 7
Sentiment
88 71 90 55
360° View
360° View
45 65 88 65
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
29 73 79 46
Opinions Change
87 23 72 50
Pro Holdings
n/a 80 73 26
Market Pulse
45 70 42 81
Sentiment
88 71 90 55
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
84 91 99 89
Growth
8 27 45 77
Safety Safety
53 39 41 7
Combined
29 53 75 71
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
68 77 82 78
Price vs. Earnings (P/E)
66 97 93 81
Price vs. Book (P/B)
89 89 91 91
Dividend Yield
72 82 81 76
Value
84 91 99 89
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
7 26 54 78
Profit Growth
72 39 48 76
Capital Growth
5 45 21 21
Stock Returns
16 39 79 79
Growth
8 27 45 77
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
35 24 34 36
Refinancing
86 88 90 1
Liquidity
32 24 28 24
Safety Safety
53 39 41 7

Similar Stocks

Discover high‑ranked alternatives to Aspen Pharmacare and broaden your portfolio horizons.

Sanlam

JNB:SLM
Country: South Africa
Industry: Life & Health Insurance
Size: Large
Full Stock Analysis

Absa

JNB:ABG
Country: South Africa
Industry: Diversified Banks
Size: Medium
Full Stock Analysis

Caxton and CTP Publishers and Printers

JNB:CAT
Country: South Africa
Industry: Publishing
Size: Medium
Full Stock Analysis

Kalbe Farma

JKT:KLBF
Country: Indonesia
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

Frequently Asked
Questions

The stock offers good value, safe financing, and positive sentiment. However, it has below-average growth expectations. It is well-suited for conservative buy-and-hold investors who prioritize stability and low valuation over growth.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews